Low Serum Carotenoids Are Associated with Self-Reported Cognitive Dysfunction and Inflammatory Markers in Breast Cancer Survivors

Overview

Journal Nutrients

Date 2018 Aug 22

PMID 30126098

Citations 12

Authors

Krystle E Zuniga

Nancy E Moran

Affiliations

Soon will be listed here.

Abstract

Dietary carotenoids may exert anti-inflammatory activities to reduce inflammation-driven cognitive impairments during cancer and cancer treatment. Our objective was to explore if cognitive function in breast cancer survivors (BCS) differs by serum carotenoid concentrations, and if blood carotenoids concentrations are associated with reduced systemic inflammation. Objective cognitive function and perceived cognitive impairment of 29 BCS and 38 controls were assessed cross-sectionally with the National Institutes of Health Toolbox Cognition Battery and The Functional Assessment of Cancer Therapy-Cognitive Function Questionnaire, respectively. Serum carotenoid and inflammatory marker (sTNF-RII, IL-6, IL-1ra, CRP) concentrations were measured. Low-carotenoid BCS had more cognitive complaints compared to the low-carotenoid controls (Mdiff = -43.0, < 0.001) and high-carotenoid controls (Mdiff = -44.5, < 0.001). However, the cognitive complaints of high-carotenoid BCS were intermediate to and not different than the low-carotenoid BCS, or low- or high-carotenoid controls. BCS performed similarly to controls on all objective cognitive measures. Multiple linear regression, controlling for age and body mass index (BMI), demonstrated an inverse association between serum carotenoid concentrations and pro-inflammatory sTNFR-II (β = 0.404, = 0.005) and IL-6 concentrations (β = -0.35, = 0.001), but not IL-1ra or CRP. Higher serum carotenoid concentrations may convey cognitive and anti-inflammatory benefits in BCS. Future research should identify dietary components and patterns that support cognitive health in cancer survivors.

Citing Articles

Relative Uptake of Tomato Carotenoids by In Vitro Intestinal and Prostate Cancer Cells.

Moran N, Alexander B, Garg S, Marchant N, Hason N J Nutr. 2024; 154(12):3639-3651.

PMID: 39393496 PMC: 11662245. DOI: 10.1016/j.tjnut.2024.10.012.

Reflection Spectroscopy-Assessed Skin Carotenoids Are Sensitive to Change in Carotenoid Intake in a 6-Week Randomized Controlled Feeding Trial in a Racially/Ethnically Diverse Sample.

Jilcott Pitts S, Moran N, Laska M, Wu Q, Harnack L, Moe S J Nutr. 2023; 153(4):1133-1142.

PMID: 36804322 PMC: 10356992. DOI: 10.1016/j.tjnut.2023.02.017.

Association of Serum Antioxidant Vitamins and Carotenoids With Incident Alzheimer Disease and All-Cause Dementia Among US Adults.

Beydoun M, Beydoun H, Fanelli-Kuczmarski M, Weiss J, Hossain S, Canas J Neurology. 2022; 98(21):e2150-e2162.

PMID: 35508396 PMC: 9169941. DOI: 10.1212/WNL.0000000000200289.

Halophilic Carotenoids and Breast Cancer: From Salt Marshes to Biomedicine.

Giani M, Montoyo-Pujol Y, Peiro G, Martinez-Espinosa R Mar Drugs. 2021; 19(11).

PMID: 34822465 PMC: 8625793. DOI: 10.3390/md19110594.

Antioxidants for the Treatment of Breast Cancer: Are We There Yet?.

Grinan-Lison C, Blaya-Canovas J, Lopez-Tejada A, Avalos-Moreno M, Navarro-Ocon A, Cara F Antioxidants (Basel). 2021; 10(2).

PMID: 33572626 PMC: 7911462. DOI: 10.3390/antiox10020205.

References

Palesh O, Scheiber C, Kesler S, Mustian K, Koopman C, Schapira L . Management of side effects during and post-treatment in breast cancer survivors. Breast J. 2017; 24(2):167-175. DOI: 10.1111/tbj.12862. View

Clarnette R, Almeida O, Forstl H, Paton A, Martins R . Clinical characteristics of individuals with subjective memory loss in Western Australia: results from a cross-sectional survey. Int J Geriatr Psychiatry. 2001; 16(2):168-74. DOI: 10.1002/1099-1166(200102)16:2<168::aid-gps291>3.0.co;2-d. View

Cheung Y, Ng T, Shwe M, Ho H, Foo K, Cham M . Association of proinflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: a multi-centered, prospective, cohort study. Ann Oncol. 2015; 26(7):1446-51. PMC: 4478978. DOI: 10.1093/annonc/mdv206. View

Nurk E, Refsum H, Drevon C, Tell G, Nygaard H, Engedal K . Cognitive performance among the elderly in relation to the intake of plant foods. The Hordaland Health Study. Br J Nutr. 2010; 104(8):1190-201. DOI: 10.1017/S0007114510001807. View

Aderka D . The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev. 1996; 7(3):231-40. DOI: 10.1016/s1359-6101(96)00026-3. View

Block G, Wakimoto P, Jensen C, Mandel S, Green R . Validation of a food frequency questionnaire for Hispanics. Prev Chronic Dis. 2006; 3(3):A77. PMC: 1636705. View

Sartori A, Vance D, Slater L, Crowe M . The impact of inflammation on cognitive function in older adults: implications for healthcare practice and research. J Neurosci Nurs. 2012; 44(4):206-17. PMC: 3390758. DOI: 10.1097/JNN.0b013e3182527690. View

Bernstein L, McCreath G, Komeylian Z, Rich J . Cognitive impairment in breast cancer survivors treated with chemotherapy depends on control group type and cognitive domains assessed: A multilevel meta-analysis. Neurosci Biobehav Rev. 2017; 83:417-428. DOI: 10.1016/j.neubiorev.2017.10.028. View

Zuniga K, MacKenzie M, Roberts S, Raine L, Hillman C, Kramer A . Relationship between fruit and vegetable intake and interference control in breast cancer survivors. Eur J Nutr. 2015; 55(4):1555-62. DOI: 10.1007/s00394-015-0973-3. View

10.

Butalla A, Crane T, Patil B, Wertheim B, Thompson P, Thomson C . Effects of a carrot juice intervention on plasma carotenoids, oxidative stress, and inflammation in overweight breast cancer survivors. Nutr Cancer. 2012; 64(2):331-41. DOI: 10.1080/01635581.2012.650779. View

11.

Milbury K, Chaoul A, Biegler K, Wangyal T, Spelman A, Meyers C . Tibetan sound meditation for cognitive dysfunction: results of a randomized controlled pilot trial. Psychooncology. 2013; 22(10):2354-63. PMC: 6083855. DOI: 10.1002/pon.3296. View

12.

Pullens M, de Vries J, Roukema J . Subjective cognitive dysfunction in breast cancer patients: a systematic review. Psychooncology. 2009; 19(11):1127-38. DOI: 10.1002/pon.1673. View

13.

Vera-Ramirez L, Ramirez-Tortosa M, Perez-Lopez P, Granados-Principal S, Battino M, Quiles J . Long-term effects of systemic cancer treatment on DNA oxidative damage: the potential for targeted therapies. Cancer Lett. 2012; 327(1-2):134-41. DOI: 10.1016/j.canlet.2011.12.029. View

14.

Lyon D, Cohen R, Chen H, Kelly D, McCain N, Starkweather A . Relationship of systemic cytokine concentrations to cognitive function over two years in women with early stage breast cancer. J Neuroimmunol. 2016; 301:74-82. PMC: 5181109. DOI: 10.1016/j.jneuroim.2016.11.002. View

15.

Miller K, Siegel R, Lin C, Mariotto A, Kramer J, Rowland J . Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016; 66(4):271-89. DOI: 10.3322/caac.21349. View

16.

Williams A, Shah R, Shayne M, Huston A, Krebs M, Murray N . Associations between inflammatory markers and cognitive function in breast cancer patients receiving chemotherapy. J Neuroimmunol. 2017; 314:17-23. PMC: 5768199. DOI: 10.1016/j.jneuroim.2017.10.005. View

17.

Shibayama O, Yoshiuchi K, Inagaki M, Matsuoka Y, Yoshikawa E, Sugawara Y . Association between adjuvant regional radiotherapy and cognitive function in breast cancer patients treated with conservation therapy. Cancer Med. 2014; 3(3):702-9. PMC: 4101762. DOI: 10.1002/cam4.174. View

18.

Lindbergh C, Renzi-Hammond L, Hammond B, Terry D, Mewborn C, Puente A . Lutein and Zeaxanthin Influence Brain Function in Older Adults: A Randomized Controlled Trial. J Int Neuropsychol Soc. 2017; 24(1):77-90. DOI: 10.1017/S1355617717000534. View

19.

Kesler S, Janelsins M, Koovakkattu D, Palesh O, Mustian K, Morrow G . Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated breast cancer survivors. Brain Behav Immun. 2012; 30 Suppl:S109-16. PMC: 3665606. DOI: 10.1016/j.bbi.2012.05.017. View

20.

Cheung Y, Foo Y, Shwe M, Tan Y, Fan G, Yong W . Minimal clinically important difference (MCID) for the functional assessment of cancer therapy: cognitive function (FACT-Cog) in breast cancer patients. J Clin Epidemiol. 2014; 67(7):811-20. DOI: 10.1016/j.jclinepi.2013.12.011. View